Capsugel expands in U.S., Europe

Contract manufacturer Capsugel is pouring millions into three facilities around the world, looking to bolster its bandwidth in soft gelatin and liquid-fill hard capsules.

PPD lures UCB exec to head immunology

PPD is working to get therapeutic area experts into its highest offices, poaching UCB's former head of immunology to lead its efforts in the field.

Quintiles seals deal for Novella

Quintiles has finalized a deal for CRO Novella Clinical, snapping up its client base of emerging drug and device developers.

CMO Aesica puts up $48M to make diabetes drugs

U.K. contract manufacturer Aesica is counting on a bullish market for solid dose diabetes drugs, and the company has poured $48 million into one of its plants to meet the demand.

Catalent lands manufacturing deal with Supernus

Catalent has partnered up with Supernus Pharmaceuticals to supply the generics maker's extended-release epilepsy drug, a product the companies say has a chance to snag a share of a big market.

InVentiv partners up for policy, site selection

CRO inVentiv Health has struck up two deals to expand its offerings, launching a policy-focused joint venture and a partnership aimed at clinical trial site selection.

Harlan ups its European presence

Indiana-headquartered CRO Harlan Laboratories has expanded its specialty research production facility in Southern Europe, offering contract breeding service for sponsors who need animal models for clinical trials.

Columbia Labs buys into CRO biz for $25M

In-transition drugmaker Columbia Laboratories is looking to cash in on the high-growth market for outsourced drug development, snatching up U.K. CRO Molecular Profiles for $25 million.

Theorem teams with Charles River on preclinical work

Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.

Bayer taps DKSH with eye on Singapore

Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.

Indian CRO TCG teams with Debiopharm for antibiotics

India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.

Italy's CROS NT reaches into U.S. with Stat-Tech buyout

Italian contract researcher CROS NT has landed in the U.S., snapping up medical device-focused CRO Stat-Tech.

Novella shuffles execs as Quintiles deal pends

Two weeks after agreeing to become part of CRO giant Quintiles, Novella Clinical is promoting from within to prepare for future growth.

MPI breaks ground on discovery-focused imaging shop

MPI Research has partnered up with two imaging outfits to open a state-of-the-art center for drug developers, and the trio has broken ground on what it calls a first-of-its-kind facility.

AMRI chief stepping down at year's end

Twenty-two years after founding the Albany contract developer, AMRI CEO Thomas D'Ambra will retire from his post on New Year's Eve, leaving the helm as the company works to get out from regulatory scrutiny and grow revenue.

Patheon posts Banner quarter on 30% sales surge

Contract manufacturer Patheon is still reaping the benefits of its high-dollar buyout of Banner Pharmacaps, wrapping up the integration process and reporting a 30.4% leap in quarterly profits.

Covance teams with Indiana U. for early trials

CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.

Capsugel snaps up Bend with eye on oral formulations

Contract manufacturer Capsugel has signed a deal to buy Oregon's Bend Research, planning to fold that company's oral drug delivery technology into its growing innovative dosing business.

FDA's pediatric rules could mean more CRO work

The FDA is adding teeth to rules requiring some drugmakers to conduct pediatric trials of new therapies, and the toughened enforcement could create an opportunity for CROs.

Report: Big CROs soared 10% last year

Despite concerns about slashed R&D budgets, overexpansion and consolidation, the titans of the CRO business are still posting double-digit growth, clocking $13.6 billion in 2012, according to a report.